

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

G. Gebhart^{1*}, L. E. Lamberts², Z. Wimana¹, C. Garcia¹, P. Emonts¹, L. Ameye¹, S. Stroobants³, M. Huizing³, P. Aftimos¹, J. Tol⁴, W. J. G. Oyen⁴, D. J. Vugts⁵, O. S. Hoekstra⁵, C. P. Schröder², C. W. Menke-van der Houven van Oordt⁵, T. Guiot¹, A. H. Brouwers², A. Awada¹, E. G. E. de Vries^{2,†} & P. Flamen^{1,†}

¹Institut Jules Bordet—Université Libre de Bruxelles (ULB), Brussels, Belgium; ²University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ³Antwerp University Hospital, Antwerpen, Belgium; ⁴Radboud University Medical Center Nijmegen, Nijmegen; ⁵VU University Medical Center Amsterdam, Amsterdam, The Netherlands

Received 29 October 2015; revised 16 November 2015; accepted 17 November 2015

Background: Only human epidermal growth factor receptor (HER)2 status determined by immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH) has been validated to predict efficacy of HER2-targeting antibody-drug-conjugate trastuzumab emtansine (T-DM1). We propose molecular imaging to explore intra-/interpatient heterogeneity in HER2 mapping of metastatic disease and to identify patients unlikely to benefit from T-DM1.

Patients and methods: HER2-positive mBC patients with IHC3+ or FISH ≥ 2.2 scheduled for T-DM1 underwent a pre-treatment HER2-positron emission tomography (PET)/computed tomography (CT) with ⁸⁹Zr-trastuzumab. [¹⁸F]2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT was performed at baseline and before T-DM1 cycle 2. Patients were grouped into four HER2-PET/CT patterns according to the proportion of FDG-avid tumor load showing relevant ⁸⁹Zr-trastuzumab uptake (>blood pool activity): patterns A and B were considered positive (>50% or all of the tumor load 'positive'); patterns C and D were considered negative (>50% or all of the tumor load 'negative'). Early FDG-PET/CT was defined as nonresponding when >50% of the tumor load showed no significant reduction of FDG uptake (<15%). Negative (NPV) and positive predictive values (PPV) of HER2-PET/CT, early FDG response and their combination were assessed to predict morphological response (RECIST 1.1) after three T-DM1 cycles and time-to-treatment failure (TTF).

Results: In the 56 patients analyzed, 29% had negative HER2-PET/CT while intrapatient heterogeneity (patterns B and C) was found in 46% of patients. Compared with RECIST1.1, respective NPV/PPV for HER2-PET/CT were 88%/72% and 83%/96% for early FDG-PET/CT. Combining HER2-PET/CT and FDG-PET/CT accurately predicted morphological response (PPV and NPV: 100%) and discriminated patients with a median TTF of only 2.8 months [$n = 12$, 95% confidence interval (CI) 1.4–7.6] from those with a TTF of 15 months ($n = 25$, 95% CI 9.7–not calculable).

Conclusions: Pretreatment imaging of HER2 targeting, combined with early metabolic response assessment holds great promise for improving the understanding of tumor heterogeneity in mBC and for selecting patients who will/will not benefit from T-DM1.

ClinicalTrials.gov identifier: NCT01565200.

Key words: HER2-positive breast cancer, HER2 imaging, prediction of T-DM1 efficacy

*Correspondence to: Dr G. Gebhart, Division of Nuclear Medicine, Jules Bordet Institute, rue Heger Bordet 1, 1000 Brussels, Belgium. Tel: +3225413240; E-mail: geraldine.gebhart@bordet.be

[†]Both authors contributed equally to this work.